A Proven Leader in Drug Development and Advocacy
Brian has made a significant impact on the pharmaceutical industry through his innovative approach to clinical pharmacology, quantitative modeling, and strategic drug development.
During his career, Brian served on drug development teams in positions of increasing responsibility across a number of therapeutic areas, culminating in his role as Senior Vice President of Translational Clinical Sciences at Pfizer. In that role he had global responsibilities for Clinical Pharmacology, Pharmacometrics, Quantitative Systems Pharmacology, Bionalytics, Precision Medicine, Digital Medicine, Imaging, Diagnostics, and Early Clinical Sciences for Pfizer Research and Development. He served on both portfolio-wide early and late-stage governance boards, providing strategic and technical review of medicine development programs across the portfolio. Brian’s interest in quantitative approaches to decision making and risk assessment led him to become Chair of the Probability of Technical and Regulatory Success (PTRS) Council, responsible for providing PTRS assessments for internal programs and external business opportunities under consideration. He served as the point of contact to direct and review line-related technical inputs for all potential acquisition and licensing opportunities. His thought leadership is exemplified by his service on various other governance and strategy committees, such as the Clinical Development AI Steering Committee, directing investments for artificial intelligence and machine learning programs related to clinical development, and the Global Standards Governance Board, working to streamline and standardize data requirements, required to facilitate process automation in analysis and reporting. His extensive experience overseeing global drug development programs, and key internal functions, positions him as a leader with both deep scientific knowledge and a forward-thinking vision for medicines development.
Brian’s leadership goes beyond drug development science. He has played a pivotal role in promoting inclusivity and diversity within the industry. As the founder of Pfizer’s Men as Allies initiative, he has been a driving force in fostering gender inclusivity in the workplace. His tenure as President of the International Society of Pharmacometrics (ISoP), and Board member of the American Society of Clinical Pharmacology and Therapeutics (ASCPT) underscores his influence in shaping the future of model informed drug development.
Brian's dedication to advancing science and advocacy has earned him numerous accolades, including the ISoP Leadership Award in 2019 for advancing the field of pharmacometrics, Pfizer’s Global Inclusive Leader Award and the University of Alberta Distinguished Alumni Award for outstanding lifetime accomplishments. Several of his scientific contributions to the field are documented in over 50 published papers, 93 peer-reviewed abstracts, and numerous invited presentations.
Strategic Advisory Solutions
The combination of Brian’s extensive industry experience and MetumRG’s market leading quantitative science and technology expertise uniquely positions the company to deliver high value and high quality Strategic Advisory Solutions to our customers.
Through strategic consulting, implementation of innovative decision making frameworks, and supporting science and technology, this offering empowers biopharma leaders to make critical data-driven decisions with confidence. Whether assessing decision quality, optimizing development plans, understanding and quantifying portfolio risk, navigating complex regulatory environments, or maximizing product value, we deliver tailored, strategic solutions designed to meet the unique needs of each client.
To learn more about MetrumRG Strategic Advisory Solutions, please click here.
About Metrum Research Group
At Metrum Research Group, we are committed to accelerating impact through scientific excellence and innovative technology solutions. For over 20 years, we’ve partnered with companies across the globe, empowering them with the tools and insights they need to drive success in drug development.